
NAME: Laura Williams Goff, MD, MSCI
INSTITUTION: Vanderbilt University Medical Center
OPEN SEAT: Society Nominating Committee Undesignated Member

A. EDUCATION, POSTDOCTORAL TRAINING, LICENSURE & CERTIFICATION

Education:

2022	M.N.H.C	(anticipated) Vanderbilt University Owen Graduate School of Management (Health Care), Nashville, TN
2008	M.S.	Vanderbilt University (Clinical Investigation), Nashville, TN
2001	M.D.	University of Texas Medical School, San Antonio, TX
1997	B.S.	Duke University (Chemistry), Durham, NC

Postdoctoral Training:

2004-2007	Fellow, Hematology-Oncology, Vanderbilt University Medical Center, Nashville, TN
2001-2004	Intern and Resident, Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX

Licensure and Certification:

2007	American Board of Internal Medicine Certification in Medical Oncology
2004	Tennessee State License
2004	American Board of Internal Medicine Certification in Internal Medicine

B. APPOINTMENTS

Academic Appointments:

2020-	Executive Medical Director, Cancer Patient Care Center, Vanderbilt University Medical Center
2018-2020	Medical Director, Hematology-Oncology, Vanderbilt University, Division of Hematology-Oncology
2016-	Associate Professor of Medicine, Vanderbilt University, Division of Hematology-Oncology
2016-2018	Service Line Chief, Medical Oncology, Vanderbilt University, Division of Hematology-Oncology
2009-2019	Associate Program Director, Vanderbilt University, Hematology-Oncology Fellowship Program
2007-2016	Assistant Professor of Medicine, Vanderbilt University, Division of Hematology-Oncology

Hospital Appointments:

2020-2021	Courtesy Staff, Vanderbilt Wilson County Hospital
2012-2016	Staff Physician, Nashville General Hospital
2007-	Staff Physician, Vanderbilt University Medical Center

2005-2007 Staff Physician, Alive Hospice

Other Employment:

1995-1997 Teaching Assistant, Duke University Chemistry Department

C. PROFESSIONAL ACTIVITIES, EDITORIAL BOARDS, AND TEACHING

Professional Activities:

Intramural Activities:

2022- Co-Chair, Professional Billing Compliance Committee
2021- Member, Vanderbilt University Medical Center Medical Board
2020- Member, Vanderbilt University Medical Center Clinical Enterprise Group
2020- Member, Vanderbilt University Medical Center Department of Medicine Executive Committee
2020- Member, Vanderbilt-Ingram Cancer Center Executive Committee
2020-2021 Invited participant in Vanderbilt University Medical Center Academic Leadership Program
2019- Advisory Committee, Vanderbilt University Medical Center Faculty Physician Parent Group
2018- Member, (Chair-Elect 2018-2019) Cancer Committee, Vanderbilt-Ingram Cancer Center. Medical Oncology representative to this committee which meets monthly to implement multidisciplinary improvements and assure that appropriate national standards are met.
2017-2018 Invited participant in Vanderbilt University Medical Center Department of Medicine Mid-Career Faculty Leadership Development Program
2016-2018 Vanderbilt University Medical Center Clinical Documentation and Coding Excellence Physician Advisor for Medical Oncology. Representative from Solid Tumor section to Vanderbilt's program to improve and sustain high quality clinical documentation and coding.
2012 Invited participant in Vanderbilt School of Medicine Research Curriculum Faculty Research Mentoring Education Initiative
2012-2018 Vanderbilt Hematology-Oncology Society. President of this society which facilitates relationships between the Vanderbilt University Alumni Society and current and former members of the Division of Hematology-Oncology.
2012 Hematology-Oncology Junior Faculty Mentorship Initiative. Worked with the division director to develop a formal mentorship process within our division for clinician educators.
2011- Vanderbilt-Ingram Cancer Center Cancer Wellness Medical Advisory Council. Medical oncology physician representative to this committee working on issues of wellness within the Cancer Center.
2011-2012 Vanderbilt University Institutional Review Board. Oncology representative to a Health Science committee established to protect the welfare of human subjects participating in biomedical research.
2009- Member, Vice-Chair (2013-2020) Vanderbilt-Ingram Cancer Center Data Safety and Monitoring Committee. Physician representative to this committee which meets quarterly and oversees patient safety and data monitoring for its investigator-initiated and NIH-NCI funded clinical trials.
2009 Vanderbilt-Ingram Cancer Center Clinical Operations Committee. Medical Oncology representative to this committee which meets monthly to oversee the clinical operations of the Cancer Center.
2008-2013 Vanderbilt-Ingram Cancer Center Quality Council, Vanderbilt University, Physician representative to this committee which meets monthly to implement and monitor initiatives to improve quality in all aspects of the Cancer Center.
2007-2008 "A" Service Ad Hoc Committee, Vanderbilt University, Member. Participated in delineating the responsibility of faculty members, fellows, and residents rotating on the inpatient oncology service in order to improve education of the house staff and continue excellent patient care.
2006-2007 House Staff Advisory Committee, Vanderbilt University, Hematology-Oncology Representative. Represented the position of the hematology-oncology fellows in this group designed to address the concerns of the Vanderbilt House Staff.
2006-2007 Hematology-Oncology Fellowship Selection Committee, Vanderbilt University, Fellow Member. Involved in interviewing and selecting fellow candidates.
2002-2004 Internal Medicine House Staff Council, University of Texas Southwestern, Member (2002-2003), President (2003-2004). Liaison between house staff and administration. Active role in recruiting new residents during the interview process.

Extramural Activities:

2021-2020-	Member, National Comprehensive Cancer Network Best Practices Committee
2020-	Member, National Comprehensive Cancer Network Guidelines Steering Committee
2020-	Member, National Comprehensive Cancer Network Board of Directors
2019-	Member, Gilda's Club of Middle Tennessee, Medical Resource Council. Physician liaison to local Gilda's Club, providing support for patients and families with cancer
2019-2020	Member, General Oncology Test Materials Development Subcommittee for the American Board of Internal Medicine/American Society of Clinical Oncology (ABIM/ASCO) Collaborative MOC Pathway
2018-2020	Member, American Society of Clinical Oncology Guidelines Panel, Systemic Therapy for Advanced Hepatocellular Carcinoma
2018, 2019	Invited mentor, Women's Networking Lounge at the American Society of Clinical Oncology Annual Meeting
2017-2020	Invited Participant, American Society of Clinical Oncology Annual Advocacy Day
2017-	Executive Committee Member, International Cholangiocarcinoma Research Network
2017-	Member, National Cancer Institute Hepatobiliary Task Force
2015	Invited Participant, American Society of Clinical Oncology Lifelong Learning Cohort
2015-2018	Member, Scientific Program Committee—Developmental Therapeutics and Translational Research-Clinical Pharmacology and Experimental Therapeutics Track, American Society of Clinical Oncology
2014-2017	Member, Professional Development Committee, American Society of Clinical Oncology
2014-2017	Member, Oncology Training Programs Subcommittee, American Society of Clinical Oncology
2014-2017	Chair, Pancreatic/Hepatobiliary Disease Work Group, GI Committee of the Eastern Cooperative Oncology Group
2014	Invited Participant at the Fibrolamellar Cancer Foundation Stakeholders Meeting
2014	Invited Participant at the Cholangiocarcinoma Foundation Stakeholders Meeting
2013-2019	Member, Scientific/Medical Advisory Committee, The Cholangiocarcinoma Foundation
2013	Invited Participant at the Angiogenesis Foundation National Expert Summit in Metastatic Colorectal Cancer
2012-2013	Junior Member, National Cancer Institute Hepatobiliary Task Force
2009-2010	Invited Participant in Oncotalk Teach, Faculty Development Program
2008	Invited Participant at the National Cancer Institute Hepatocellular Carcinoma State of the Science Meeting
2008	Invited Panel member for the National Comprehensive Cancer Network (NCCN) Guidelines for the Management of Hepatobiliary Cancers
2006	Invited Participant in Oncotalk, Improving Communication Skills for Oncology Fellows
2006	Invited Participant in AACR/ASCO Vail Workshop, Methods in Clinical Cancer Research, Mentor: Daniel Von Hoff

Editorial Responsibilities:

2009- Editorial board member, Momentum Magazine

Review Responsibilities:

Reviewer, Cancer Investigation
Reviewer, Cancer Control Journal
Reviewer, American Journal of Clinical Oncology
Reviewer, Journal of Clinical Oncology
Reviewer, Annals of Surgical Oncology
Reviewer, Investigational New Drugs
Reviewer, Clinical Cancer Research
Reviewer, Journal of the American Medical Association Oncology
Reviewer, BMC Cancer
Reviewer, The Oncologist
Reviewer, Scientific Reports
Reviewer, Clinical and Translational Gastroenterology

Teaching Activities:

Medical School Courses:

2008 Discussion leader, Vanderbilt University Medical Center Capstone course, colorectal cancer module

Graduate School Courses:

2008- Director, Vanderbilt Hematology/Oncology Fellows Seminar Series. Responsible for developing the weekly didactic lecture series for the fellows in order to satisfy educational needs and cover a core curriculum.

Selected Lectures:

2021 "Systemic Therapy for Hepatobiliary Cancers" Liver Transplant Didactic Series, Vanderbilt University Medical Center
2021 "Hepatobiliary Cancers" Fellows Division Seminar, Vanderbilt University Medical Center
2020 "Hepatobiliary Cancers" Fellows Division Seminar, Vanderbilt University Medical Center
2020 "Update on HCC" American Liver Foundation Nashville Liver Focus, given virtually
2019 "Hepatobiliary Cancers" Radiation Oncology Residency Program Didactic Series, Vanderbilt University Medical Center
2019 "Hepatobiliary Cancers" Fellows Division Seminar, Vanderbilt University Medical Center
2018 "Hepatobiliary Cancers" Fellows Division Seminar, Vanderbilt University Medical Center
2017 "GI Cancers" Cardio-oncology Fellowship Didactic Series, Vanderbilt University Medical Center
2017 "Esophagogastric Cancers" Fellows Division Seminar, Vanderbilt University Medical Center
2017 "Got Feedback" Hematology-Oncology Division Conference, Vanderbilt University Medical Center
2016 "How I use our In-Training Exam Scores" American Society of Clinical Oncology Program Directors' Retreat
2015 "Esophagogastric Cancers" Fellows Division Seminar, Vanderbilt University Medical Center
2014 "Esophagogastric Cancers" Fellows Division Seminar, Vanderbilt University Medical Center
2013 "Colorectal Cancer" Internal Medicine Residents' Didactic Series, Meharry Medical College
2013 "Gastric Cancer" Fellows Division Seminar, Vanderbilt University Medical Center
2013 "Esophageal Cancer" Fellows Division Seminar, Vanderbilt University Medical Center
2013 "Frankly Speaking about Colorectal Cancer" Gilda's Club
2012 "Adjuvant Treatment for Colorectal Cancer" Fellows Division Seminar, Vanderbilt University Medical Center
2012 "GI Cancers" Internal Medicine Residents' Didactic Series
2011 "Non-Metastatic Colon and Rectal Cancer" Fellows Division Seminar, Vanderbilt University Medical Center
2011 "Esophageal and Gastric Cancers" Fellows Division Seminar, Vanderbilt University Medical Center
2009 "Oncologic Emergencies" Fellows Division Seminar, Vanderbilt University Medical Center
2008 "Hepatobiliary Tumors" Fellows Division Seminar, Vanderbilt University Medical Center
2007 "Pathophysiology of Cancer" Primary Care Nurse Practitioner Program Pathophysiology Course, Vanderbilt University School of Nursing
2007 "Non-metastatic Colorectal Cancer" Fellows Division Seminar, Vanderbilt University Medical Center
2005 "Rash and EGFR Inhibitors." Fellows Division Seminar, Vanderbilt University Medical Center

Continuing Medical Education:

2021 "Systemic Therapy for Hepatocellular Carcinoma" ASCO Education eLearning Online Course
2021 "Great Debates in GI Cancers: Hepatobiliary Cancers," given virtually, faculty lecturer and panel discussant
2021 "OncoLive 2021 Institutional Perspectives in Cancer: Gastrointestinal Malignancies," given virtually, faculty lecturer
2018 "Developmental Therapeutics" Best of ASCO, lecturer
2015 "Updates in Upper GI Cancers" Owensboro Fall Oncology Conference, lecturer
2015 "Developmental Therapeutics" Best of ASCO, lecturer
2015 "Updates in Upper GI Cancers" Vanderbilt-Ingram Cancer Center's Hematology-Oncology Education Symposium, lecturer
2014 "Upper GI Cancers" Vanderbilt-Ingram Cancer Center's Hematology-Oncology Education Symposium, lecturer

2014	"Medical Management of Metastatic Pancreatic Neuroendocrine Tumors" Multidisciplinary Management of Diseases of the Pancreas, lecturer
2014	"Biliary Tract Malignancies" Scripps' 34 th Annual Conference: Clinical Hematology & Oncology, lecturer
2013	"Medical Management of Metastatic Pancreatic Neuroendocrine Tumors" Multidisciplinary Management of Diseases of the Pancreas, lecturer
2011	"Highlights in Hepatobiliary Cancers 2011" Vanderbilt-Ingram Cancer Center's Eighth Annual Hematology-Oncology Review Symposium, lecturer
2010	Co-Chair, Vanderbilt-Ingram Cancer Center Seventh Annual Oncology Review Symposium. Organized speakers and presentations for the annual update regarding advances in oncology presented in the previous year.
2010	"New Targets in the Treatment of Hepatocellular Carcinoma" Medical Grand Rounds, Vanderbilt University Medical Center, lecturer
2009	"Therapeutic Options for Pancreas Cancer" Vanderbilt Digestive Disease Center Gastroenterology and Hepatology Update, lecturer
2009	"Highlights in Upper GI Cancers 2009" Vanderbilt-Ingram Cancer Center's Sixth Annual Oncology Review Symposium, lecturer
2009	"Novel Targets in Colorectal Cancer" Vanderbilt-Ingram Cancer Center Affiliate Network Spring \ Scientific Review, lecturer
2009	"Multidisciplinary Management of Hepatocellular Carcinoma" Surgical Grand Rounds, Vanderbilt University Medical Center, lecturer
2008	"New Options for the Treatment of Hepatocellular Carcinoma" Vanderbilt-Ingram Cancer Center Affiliate Network Fall Oncology Conference, lecturer
2008	"Hepatobiliary Cancers at ASCO 2008" Vanderbilt-Ingram Cancer Center's Fifth Annual Oncology Review Symposium, lecturer
2007	"New Hope with Targeted Therapy for Hepatocellular Carcinoma" ENACT HCC/CME Innovations, lecturer
2007	"Hepatocellular Carcinoma" Oncology Nursing Society Meeting, lecturer
2005	"Post-Transplant Lymphoproliferative Disorders." Hematology Grand Rounds, Vanderbilt University Medical Center, lecturer

Clinical Teaching:

2007-	Key Clinical Faculty member, Vanderbilt University Medical Center Hematology-Oncology Fellowship Program. Responsible for weekly teaching in clinic for medical students, residents, and fellows.
2004-2007	Fellow, Vanderbilt University Medical Center. Responsible for bedside and didactic teaching of medical students and residents.
2001-2004	Resident, University of Texas Southwestern Medical Center. Responsible for bedside and didactic teaching of medical students and residents.
1999-2000	Mentor to first year students, University of Texas Medical School at San Antonio

D. RESEARCH, GRANTS, AND TRIALS

Research Supervision:

2021-	Justin Lo, MD, PhD, Fellow in Oncology at Vanderbilt University Medical Center
2016-2017	Marc Roth, MD, Physician, Sarah Cannon Research Institute
2013-2014	Fyza Shaikh, MD, PhD, Instructor in Oncology at Johns Hopkins University
2011-2013	Kristen Ciombor, MD, Associate Professor at Vanderbilt University Medical Center

Grant Reviewer:

Cholangiocarcinoma Foundation
 Medical Research Council United Kingdom

Data Safety Monitoring Committees:

Newlinks Genetics, Chair

Other Significant Activities:

2012- Belmont United Methodist Church Children's Ministry Team

Research Program:

Clinical Trials:

Investigator Initiated Clinical Trials:

- GI 0622: A Phase I/II Clinical and Biological Evaluation of Combined EGFR Blockade with Erlotinib and Cetuximab in Patients with Advanced Cancer (Phase I) or Advanced Colorectal Cancer (Phase II). Role: Principal Investigator
- GI 0716, Pharmacogenomically Selected Treatment for Gastric and Gastroesophageal Junction (GEJ) Tumors: A Phase II Study. Role: Principal Investigator.
- GI 0726: A Phase 2 Study of AZD6244 in Advanced or Metastatic Hepatocellular Carcinoma. Role: Local Principal Investigator.
- GI 0811: A Phase 2 Study of AZD6244 in Biliary Cancers. Role: Local Principal Investigator.
- GI 0906: A Phase Ib Trial of Gemcitabine and Oxaliplatin (GEMOX) with Erlotinib in Patients with Advanced Biliary Tract Cancer. Role: National Principal Investigator of this Investigator-Initiated Trial.
- GI 0947: A Phase II Trial of Temsirolimus and Bevacizumab in Patients with Endometrial, Ovarian, Hepatocellular Carcinoma, Carcinoid or Islet Cell Cancer. Role: Local Principal Investigator.
- NCI 9824: A phase 1 study of alisertib (MLN8237) in combination with mFOLFOX in gastrointestinal tumors. Role: National Principal Investigator.
- GI 17112: A Phase 1/2 Study of Olaparib in Combination with Ramucirumab in Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma. Role: Local Principal Investigator.
- GI 1812: A Randomized Phase 2 Study of Atezolizumab in Combination with Cobimetinib versus Atezolizumab Monotherapy in Participants with Unresectable Cholangiocarcinoma. Role: Local Principal Investigator. ECOGIS1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers. Role: ECOG-ACRIN Study Chair.
- GI 1915: Phase II Multi-Center Study of PARP Inhibitor Rucaparib in Combination with Anti-PD-1 Antibody Nivolumab in Patients with Advanced or Metastatic Biliary Tract Cancer Following Platinum Therapy. Role: Local Principal Investigator.
- GI 20110: A Randomized Phase II Study of Atezolizumab and Bevacizumab with Y90 TARE in Patients with Unresectable Hepatocellular Carcinoma. Role: Local Principal Investigator. ECOGGIEA2187: A Phase 2 Study of Pevonedistat in Combination with Carboplatin and Paclitaxel in Advanced Intrahepatic Cholangiocarcinoma. Role: Local Principal Investigator.
- GIP2159: A Multi-Center Randomized Phase IB/II Study of Gemcitabine and Cisplatin with or without CPI-613 as First Line Therapy for Patients with Advanced Unresectable Biliary Tract Cancer (BiIT-04). Role: Local Principal Investigator.
- NCIGI10476: A Randomized Phase 2 Study of Combination Atezolizumab and CDX-1127 (Varlilumab) with or without Addition of Cobimetinib in Previously Treated Unresectable Biliary Tract Cancers. Role: Local Principal Investigator.
- ECOGGIEA2197: Optimal Perioperative Therapy for Incidental Gallbladder Cancer (OPT-IN): A Randomized Phase II/III Trial. Role: Local Principal Investigator.

Pharmaceutical Industry Clinical Trials:

- GI 0701: A Phase II, Open Label, Multiple Center Study of huC242-DM4 Given as an Intravenous Infusion Once Every Three Weeks to Patients with Metastatic Gastric or Gastroesophageal Junction (GEJ) Carcinomas. Role: Local Principal Investigator.
- GI 0943: A Randomized, Double-Blind, Multicenter Phase III Study of Brivanib Versus Placebo as Adjuvant Therapy to Trans-Arterial Chemo-Embolization (TACE) in Patients with Unresectable Hepatocellular Carcinoma: The BRISK TA Study. Role: Local Principal Investigator.
- GI 0960: Phase 2, Randomized Study of CS-1008 in Combination with Sorafenib Compared to Sorafenib Alone as First-Line Systemic Therapy in Subjects with Advanced Hepatocellular Carcinoma. Role: Local Principal Investigator.
- GI 1068: A Phase 1 Dose Escalation Study of MLN8237, an Aurora A Kinase Inhibitor, in Adult Patients with Nonhematological Malignancies, Followed by a Phase 2 of MLN8237 in Lung, Breast, Head and Neck, or Gastroesophageal Malignancies. Role: Local Principal Investigator.
- GI 1183: A Randomized, Placebo-controlled, Double-blind, Multicenter Phase II Trial of Intravenous GC33 at

- 1600 mg Q2W in Previously Treated Patients with Unresectable Advanced or Metastatic Hepatocellular Carcinoma (HCC). Role: Local Principal Investigator.
- GI 1534: A Phase 1 Pharmacokinetic and Safety Study of Paclitaxel Injection Concentrate for Nano-dispersion (PICN) Alone and in Combination with Carboplatin in Subjects with Advanced Solid Malignancies. Role: Local Principal Investigator.
- PHI 15114: An Open-Label, Multicenter, Phase 1 Study of Ramucirumab plus MEDI4736 in Patients with Locally Advanced and Unresectable or Metastatic Gastrointestinal or Thoracic Malignancies. Role: International Tumor Lead (Hepatocellular Cancer).
- GI 15146: A Multicenter, Randomized, Open-label Study in Patients with Esophageal Cancer Refractory or Intolerant to Combination Therapy with Fluoropyrimidine and Platinum-based Drugs. Role: Local Principal Investigator.
- GI 1631: Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib or Placebo plus Cisplatin and Gemcitabine as First-Line Treatment in Patients with Advanced or Metastatic Biliary Tract Cancer. Role: Local Principal Investigator.
- GI 1655: A Randomized, Multicenter, Double Blind, Phase III Study of Adjuvant Nivolumab or Placebo in Subjects with Resected Esophageal, or Gastroesophageal Junction Cancer. Role: Local Principal Investigator.
- GI 13114: A Multi Part, Phase 1, Multi-center, Open-label Study of DKN-01 as Monotherapy or in Combination with Paclitaxel or Pembrolizumab in Patients with Relapsed or Refractory Esophagogastric Malignancies. Role: Local Principal Investigator.
- GI 16149: An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects with Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma. Role: Local Principal Investigator.
- MD 16159: A Phase 1/2 Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of Azacitidine in Combination with Pembrolizumab and Epcadostat in Subjects with Advanced Solid Tumors and Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Stage IV Microsatellite-Stable Colorectal Cancer. Role: Local Principal Investigator.
- GI 1721: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of AG-120 in Previously-Treated Subjects with Nonresectable or Metastatic Cholangiocarcinoma with an IDH1 Mutation. Role: Local Principal Investigator.
- GI 1754: A Pivotal Trial of Derazantinib in Subjects with FGFR2 Gene Fusion Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma. Role: Local Principal Investigator.
- GI 1843: A Randomized, Open-label, Multicenter Phase 3 Study to Compare the Efficacy and Safety of BGB-A317 versus Sorafenib as First-Line Treatment in Patients with Unresectable Hepatocellular Carcinoma. Role: Local Principal Investigator.
- GI 1869: A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Varlitinib plus Capecitabine versus Placebo plus Capecitabine in Patients with Advanced or Metastatic Biliary Tract Cancer as Second-Line Systemic Therapy. Role: Local Principal Investigator.
- GI 1924: A Phase 3 Double-Blinded, Two-Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab versus Placebo as Adjuvant Therapy in Participants with Hepatocellular Carcinoma and Complete Radiological Response after Surgical Resection or Local Ablation. Role: Local Principal Investigator.

Cumulative Listing of All Grants:

- 1U10CA180847-01 (Berlin) 04/17/2014 – 02/28/2019 (0.36 Calendar Months) NCI, Vanderbilt Network Lead Academic Participating Site for the NCTN. Partial salary support.
- CA186689-01 (Berlin) 03/01/2014-02/28/2019 NIH, ViKTriY Early Clinical Trials Consortium. Partial salary support for role as National Principal Investigator of NCI 9824.
- U10CA021115-39 Subaward VANO39LG-00 (Goff) 03/01/2014-01/31/2016, Frontier Science & Technology Research Foundation/ECOG-ACRIN. Partial salary support for role as ECOG-ACRIN Pancreas-Hepatobiliary Working Group Chair.
- Cholangiocarcinoma Foundation Research Grant (Kelley) 01/01/2015-12/31/2015, Second Line Chemotherapy in Advanced Biliary Cancer. Funding for a three institution (UCSF, Vanderbilt and Memorial Sloan Kettering) retrospective analysis of outcomes in advanced biliary cancers.
- 5U10CA107612-09 (Wolff) 06/01/2013-05/31/2014 (2.4 Calendar Months), NCI (Meharry Medical College) Minority Based Community Clinical Oncology Program at Meharry Medical College. The main goal of the project is to provide diagnoses, stages, and treatment of cancer patients that are identified to be eligible for clinical trial participation.
- 2K12 CA090562-06 (Hande, Kenneth), Salary and tuition support to participate in the Master of Science in Clinical Investigation Program
- 5M10RR000095-46 (Balsler, Jeffrey), General Clinical Research Center subproject funding support of "Pilot study of the effects of EGFR inhibitors on magnesium homeostasis." Role: Subproject Principal Investigator.

- 5P50 CA095103-05 (Coffey, Robert J), GI SPORE subproject funding support of "Pilot study of the effects of epidermal growth factor receptor (EGFR) inhibitors on the EGFR in skin lesions." Role: Subproject Principal Investigator.
- N01-CM-62208 (Sandler, Alan) Southeast Phase II Consortium subproject funding of "A Phase 2 Study of AZD6244 in Advanced or Metastatic Hepatocellular Carcinoma." Role: Local Subproject Principal Investigator.
- N01-CM-62208 (Sandler, Alan) Southeast Phase II Consortium subproject funding of "A Phase 2 Study of AZD6244 in Biliary Cancers." Role: Local Subproject Principal Investigator.
- 1R21 CA123881 (Lockhart, A. Craig) Pharmacogenomically Selected Treatment for Gastric and Gastroesophageal Junction Tumors. Role: Local Principal Investigator.
- 5P50 CA095103-05 (Coffey, Robert J), GI SPORE subproject funding support of "A Phase I/II Clinical and Biological Evaluation of Combined EGFR Blockade with Erlotinib and Cetuximab in Patients with Advanced Cancer (Phase I) or Advanced Colorectal Cancer (Phase II)." Role: Clinical Trial Principal Investigator.

E. BIBLIOGRAPHY

Articles in refereed journals:

1. **Goff LW**, Rothenberg ML, Lockhart AC, Roth BJ, VerMeulen WL, Chan E, Berlin JD. Phase I trial of irinotecan alternating with epirubicin in patients with advanced malignancies. *American Journal of Clinical Oncology*, 31: 413-416, 2008.
2. Benson AB3rd, Abrams TA, Ben-Josef E, Bloomston PM, Botha JF, Clary BM, Covey A, Curley SA, D'Angelica MI, Davila R, Ensminger WD, Gibbs JF, Laheru D, Malafa MP, Marrero J, Meranze SG, Mulvihill SJ, Park JO, Posey JA, Sachdev J, Salem R, Sigurdson ER, Sofocleous C, Vauthey JN, Venook AP, **Goff LW**, Yen Y, Zhu AX. NCCN Clinical Practice Guidelines in Oncology: Hepatobiliary Cancers. *Journal of the National Comprehensive Cancer Network*, 7(4): 350-91, 2009
3. O'Neil BH, **Goff LW**, Kauh JSW, Strosberg JR, Bekaii-Saab TS, Lee RM, Kazi a, Moore DT, Learoyd M, Lush RM, Sebti SM, Sullivan DM. A phase II study of the MEK inhibitor selumetinib in patients with advanced hepatocellular carcinoma. *Journal of Clinical Oncology*, 29(17): 2350-6, 2011. PMID: PMC3107750
4. Bekaii-Saab TS, Phelps MA, Li X, Saji M, **Goff LW**, Kauh JSW, O'Neil BH, Balsom S, Balint C, Liersemann R, Vasko VV, Boomston M, Marsh W, Doyle LA, Ellison G, Grever M, Ringel MD, Villalona-Calero MA. A multi-institutional phase II study of selumetinib (AZD6244, ARRY142886) in patients with metastatic biliary cancers. *Journal of Clinical Oncology*, 29(17): 2357-63, 2011. PMID: PMC3107751
5. **Goff LW**, Benson AB, LoRusso PM, Tan AR, Berlin JD, Denis LJ, Benner RJ, Yin D, Rothenberg ML. Phase I study of oral irinotecan as a single-agent and given sequentially with capecitabine. *Investigational New Drugs*, 30: 290-298, 2012.
6. Infante JR, Bendell JC, **Goff LW**, Jones SF, Chan E, Sudo T, Burriss HA, Berlin JD. A phase 1 study of KRN330, an anti-A33 fully-human monoclonal antibody, in patients with metastatic colorectal cancer. *European Journal of Cancer*, 49(6): 1169-75, 2013.
7. Cardin D, **Goff L**, Li C, Shyr Y, Winkler C, DeVore R, Schlabach L, Holloway M, McClanahan P, Meyer K, Grigorieva J, Berlin J, Chan E. A phase II study of sorafenib and erlotinib in advanced pancreatic cancer. *Cancer Medicine*, 3(3): 572-9, 2014. PMID: PMC4101748.
8. Johnson DB, Dahlman KB, Knol J, Gilbert J, Puzanov I, Means-Powell J, Balko JM, Lovly CM, Murphy BA, **Goff LW**, Abramson VG, Crispens MA, Mayer I, Berlin J, Horn L, Keedy V, Reddy NM, Arteaga CL, Sosman J, Pao W. Enabling a genetically-informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel. *The Oncologist*, 19(6):616-22, 2014. PMID: PMC4041676.
9. **Goff LW**, Thakkar N, Du L, Chan E, Tan BR, Cardin DB, McLeod HL, Berlin JD, Zehnbauser B, Fournier C, Picus J, Wang-Gillam A, Lee W, Lockhart AC. Thymidylate synthase genotype-directed chemotherapy for patients with gastric and gastroesophageal junction cancers. *PLOS ONE*, 9(9):e107424, 2014. PMID: PMC4169411.
10. Puzanov I, Lindsay CR, **Goff L**, Sosman J, Gilbert J, Berlin J, Poondru S, Simantov R, Gedrich R, Stephens A, Chan E, Evans JT. A phase I study of continuous oral dosing of OSI-906, a dual inhibitor of insulin growth factor-1 and insulin receptor tyrosine kinases in patients with advanced solid tumors. *Clinical Cancer Research*, 21(4): 701-11, 2015.
11. Puzanov I, Sosman J, Santoro A, Saif MW, **Goff LW**, Dy G, Zucali P, Means-Powell JA, Ma W, Simonelli M, Martell R, Chai F, Lamar M, Savage RE, Schwartz B, Adjei A. Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors. *Investigational New Drugs*, 33(1): 159-168, 2015. PMID: PMC4295023.
12. **Goff LW**, Cohen RB, Berlin JD, DeBraud FG, Lyschik A, Noberasco C, Bertolini F, Carpentieri M, Gallo Stampino C, Abbattista A, Wang E, Borghaei H. A phase 1 study of the anti-activin receptor-like kinase 1 (ALK-1)

antibody PF-03446962 in patients with advanced solid tumors. *Clinical Cancer Research* 22(9): 2146-54, May 1, 2016.

13. Chan E, Arlinghaus LR, Cardin DB, **Goff LW**, Berlin JD, Parikh A, Abramson RG, Yankeelov T, Merchant N, Hiebert S, Chakravarthy AB. Phase I trial of chemoradiation with capecitabine and vorinostat in pancreatic cancer. *Radiotherapy and Oncology*, 119(2):312-8, May 2016. PMID: PMC4961249
14. **Goff LW**, Cardin DB, Whisenant JG, Du L, Koyama T, Dahlman KB, Salaria SN, Young RT, Ciombor KK, Gilbert J, Smith SJ, Chan E, Berlin J. A phase I trial investigating pulsatile erlotinib in combination with gemcitabine and oxaliplatin in advanced biliary tract cancers. *Investigational New Drugs*, 35(1): 95-104, February 2017. PMID: PMC5306261
15. Chan E, **Goff LW**, Cardin DB, Ancell KK, Smith SJ, Whisenant JG, Ye F, Berlin JD. Phase II study of the multikinase inhibitor of angiogenesis, linifanib, in patients with metastatic and refractory colorectal cancer expressing mutated *KRAS*. *Investigational New Drugs*, 35(4): 491-498, Aug 2017. PMID: 26353122.
16. Cardin DB, Thota R, **Goff LW**, Berlin JD, Jones CM, Ayers GD, Whisenant JG, Chan E. A phase II study of ganetespib as second-line or third-line therapy for metastatic pancreatic cancer. *American Journal of Clinical Oncology*, 41(8): 772-776, Aug 2018. PMID: PMC5599313.
17. Cardin DB, **Goff LW**, Chan E, Whisenant JG, Ayers G, Takebe N, Arlinghaus LR, Yankeelov TE, Berlin J, Merchant N. Dual Src and EGFR inhibition in combination with gemcitabine in advanced pancreatic cancer: phase I results: A phase I clinical trial. *Investigational New Drugs*, 36(3): 442-450, 2018. PMID: [PMC5891394](#).
18. Das S, Wright JK, **Goff L**, Chakravarthy A, Chan E. Brachytherapy boost to tumor bed prior to adjuvant chemoradiation in margin positive resected cholangiocarcinoma. *Clinical Oncology: Case Reports*, 2018.
19. Das S, Pineda G, **Goff L**, Sobel R, Berlin J, Fisher G. The eye of the beholder: orbital metastases from midgut neuroendocrine tumors, a two institution experience *Cancer Imaging*, 18(1): 47, 2018. PMID: PMC6262338.
20. **Goff LW**, Azad NS, Stein S, Whisenant JG, Koyama T, Vaishampayan U, Hochster H, Connolly R, Weise A, LoRusso PM, Salaria SN, El-Rifai W, Berlin JD. Phase I study combining the aurora kinase A inhibitor alisertib with mFOLFOX in gastrointestinal cancer. *Investigational New Drugs*, 37(2): 315-322, April 2019. PMID: 30191522. PMID: PMC6401337.
21. Saba NF, Force S, Staley C, Fernandez F, Willingham F, Pickens A, Cardona K, Chen Z, **Goff L**, Cardin D, Lambright E, Nesbitt J, Krasinskas A, Higgins K, Harvey RD, Owonikoko T, Ramalingam SS, Shin DM, Beitler JJ, El-Rayes BF, Salaria S, El-Rifai W, Landry J, Chakravarthy AB. Phase IB study of induction chemotherapy with XELOX, followed by radiation therapy, carboplatin, and everolimus in patients with locally advanced esophageal cancer. *American Journal of Clinical Oncology* 42(4): 331-336, 2019. PMID: PMC6433493.
22. Lowery MA, **Goff LW**, Keenan BP, Jordan E, Wang R, Bocobo AG, Chou JF, O'Reilly EM, Harding JJ, Kemeny N, Capanu M, Griffin AC, McGuire J, Venook AP, Abou-Alfa GK, Kelley RK. Second line chemotherapy in advanced biliary cancers: a retrospective, multicenter analysis of outcomes. *Cancer* 125(24): 4426-4434, 2019.
23. Wei AC, Ou F, Shi Q, Carrero X, O'Reilly EM, Meyerhardt J, Wolff RA, Kindler HL, Evans DB, Deshpande V, Misraji J, Tamm E, Sahani D, Moore M, Newman E, Merchant N, Berlin J, **Goff LW**, Pisters P, Posner MP. Perioperative gemcitabine+erlotinib plus pancreaticoduodenectomy for resectable pancreatic adenocarcinoma: ACOSOG Z5041 (Alliance) phase II trial. *Annals of Surgical Oncology*, 26(13): 4489-4497, 2019.
24. Nordness MF, Hamel S, Godfrey CM, Shi C, Johnson DB, **Goff LW**, Perri RE, Alexopoulos SP. Fatal hepatic necrosis after nivolumab as a bridge to liver transplant for HCC: Are checkpoint inhibitors safe for the pretransplant patient? *American Journal of Transplantation*. 20(3): 879-883, 2020. PMID: 31550417.
25. Das S, Ciombor KK, Haraldsdottir S, Pumpalova Y, Sahin IH, Pineda G, Shyr Y, Lin EP, Hsu CY, Chu SK, **Goff LW**, Cardin DB, Bilen MA, Fisher GA, Wu C, Berlin J. Immune-related adverse events and immune checkpoint inhibitor efficacy in patients with gastrointestinal cancer with Food and Drug Administration-approved indications for immunotherapy. *Oncologist*, 25(8): 669-679, 2020. PMID: 31943525
26. Bang YJ, Golan T, Dahan L, Fu S, Moreno V, Park K, Geva R, De Braud F, Wainberg ZA, Reck M, **Goff L**, Laing N, Mi G, Oliveira JM, Wasserstrom H, Lin CC. Ramucirumab and durvalumab for previously treated, advanced non-small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: an open-label phase Ia/b study (JVDJ). *European Journal of Cancer*, 137:272-284, 2020. PMID: 32827847
27. Das S, Du L, Schad A, Jain S, Jessop A, Shah C, Eisner D, Cardin D, Ciombor K, **Goff L**, Bradshaw M, Delbeke D, Sandler M, Berlin J. A clinical score for neuroendocrine tumor patients under consideration for Lu-177-Dotatate therapy. *Endocrine Related Cancer*, 28(3):203-212, Mar 2021. PMID: 33608484. PMID: PMC8026653.
28. Kelly RJ, Ajani JA, Kuzdzal J, Zander T, Van Cutsem E, Piessen G, Mendez G, Feliciano J, Motoyama S, Lievre A, Uronis H, Elimova E, Grootscholten C, Geboes K, Zafar S, Snow S, Ko AH, Feeney K, Schenker M, Kocon P, Zhang J, Zhu L, Lei M, Singh P, Kondo K, Cleary JM, CheckMate 577 Investigators (**Acknowledged Investigator**) Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. *New England Journal of Medicine* 384(13):1191-1203, Apr 2021. PMID: 33789008.
29. Cohen AS, Grudzinski J, Smith GT, Peterson TE, Whisenant JG, Hickman TL, Ciombor KK, Cardin D, Eng C, **Goff LW**, Das S, Coffey RJ, Berlin JD, Manning HC. First-in-human PET imaging and estimated radiation dosimetry of L-[5-¹¹C]-glutamine in patients with metastatic colorectal cancer. *Journal of Nuclear Medicine*, Online ahead of print, Apr 2021. PMID: 33931465.

30. Ma WW, Zhu M, Lam ET, Diamond JR, Dy GK, Fisher GA, **Goff LW**, Alberts S, Bui LA, Sanghal A, Kothekar M, Khopade A, Chimote G, Falkner R, Eckhardt SG, Adjei AA, Jimeno A. A phase I pharmacokinetic and safety study of Paclitaxel Injection Concentrate for Nano-dispersion (PICN) alone and in combination with carboplatin in patients with advanced solid malignancies and biliary tract cancers. *Cancer Chemotherapy and Pharmacology* 87(6):779-788, Jun 2021. PMID: 3364324.
31. Yarchoan M, Cope L, Ruggieri AN, Anders RA, Noonan A, **Goff LW**, Goyal L, Lacy J, Li D, Patel AK, He AR, Abou-Alfa GK, Spencer K, Kim EJ, Davis SL, McRee AJ, Kunk PR, Goyal S, Liu Y, Dennison L, Xavier S, Mohan AA, Zhu Q, Wang-Gillam A, Poklepovi A, Chen HX, Sharon E, Lesinski GB, Azad NS. Multicenter randomized phase II trial of atezolizumab with or without cobimetinib in biliary tract cancers. *Journal of Clinical Investigation* 131(24):e152670, Dec 15, 2021. PMID: 34907910. PMCID: PMC8670844.
32. Das S, Chauhan A, Du L, Thomas KE, Jacob A, Schad A, Jain S, Jessop A, Shah C, Eisner D, Cardin DB, Ciombor KK, **Goff LW**, Bradshaw M, Delbeke D, Sandler M, Ramirez RA, Berlin J. External validation of a clinical score for patients with neuroendocrine tumors under consideration for peptide receptor radionuclide therapy. *JAMA Network Open* 5(1):e2144170, Jan 4, 2022. PMID:35044469. PMCID: PMC8771294.
33. Barrett TW, Garland NM, Freeman CL, Klar K, Dahlke J, Lancaster P, Prisco L, Chang SS, **Goff LW**, Russ S, Jones ID. Catching those who fall through the cracks: integrating a follow-up process for emergency department patients with incidental radiologic findings. *Annals of Emergency Medicine*. Accepted for publication, 2022.

Books, book chapters, invited review articles:

1. Stinnett SE, **Williams LA**, Johnson DH. Role of chemotherapy for palliation in the lung cancer patient. *The Journal of Supportive Oncology*, 5:19-24, 2007.
2. **Williams LA**, Berlin JD. Approach to Cholangiocarcinoma: Chemotherapy. In: Jankowski J, Sampliner RE, Kerr DJ and Fong Y, eds. *GI Oncology: A Critical Multidisciplinary Team Approach*. Hoboken, NJ: Wiley-Blackwell; 2008.
3. Dar AA, **Goff LW**, Majid S, Berlin J, El-Rifai W. Aurora kinase inhibitors-rising stars in cancer therapeutics? *Molecular Cancer Therapeutics*, 9(2): 268-278, 2010. PMCID: PMC2820587
4. Mukherjee K, Chakravarthy AB, **Goff LW**, El-Rifai W. Esophageal adenocarcinoma: treatment modalities in the era of targeted therapy. *Digestive Diseases and Sciences*, 55(12): 3304-14, 2010. PMCID: PMC2890301
5. Ewing GP, **Goff LW**. The insulin-like growth factor signaling pathway as a target for treatment of colorectal carcinoma. *Clinical Colorectal Cancer*, 9: 219-223, 2010.
6. Watson GT, **Goff LW**, Shi C, Pohlmann P. Molecular profiling of gastric cancer. Retrieved from <http://www.mycancergenome.org/content/disease/gastric-cancer>, 2012.
7. Colonna SV, Berlin JD, **Goff LW**. "Biliary Tract Cancers" for Decision Support in Medicine (Clinical Decision Support: Oncology). Retrieved from www.decisionsupportinmedicine.com, 2013.
8. Chi M, Mikhitarian K, Shi Chi, **Goff LW**. Management of combined hepatocellular-cholangiocarcinoma: a case report and literature review. *Gastrointestinal Cancer Research*, 5(6): 199-202, 2012. PMCID: PMC3533848.
9. **Goff LW**, Berlin JD. Advanced biliary tract cancers. *ASCO Educational Book*, 281-282; 2012.
10. Ciombor KK, **Goff LW**. Advances in the management of biliary tract cancers. *Clinical Advances in Hematology & Oncology*, 11(1): 28-34, 2013. PMCID: PMC3713630.
11. Venepalli NK, **Goff LW**. Targeting the HGF-cMET axis in hepatocellular carcinoma. *International Journal of Hepatology*, Mar 31 2013 [Epub]. PMCID: PMC3626399.
12. Ciombor KK, **Goff LW**. Current therapy and future directions in biliary tract malignancies. *Current Treatment Options Oncology*, 14(3): 337-49, 2013. PMCID: PMC3769474.
13. **Goff L**. Chemotherapy for the Treatment of Synchronous Stage IV Disease. In Benson AB, Chakravarthy AB, Hamilton SR, Sigurdson ER, eds. *Cancers of the Colon and Rectum: A Multidisciplinary Approach to Diagnosis and Management*. New York, NY: Demos Medical Publishing; 2014.
14. Katsha A, Belkhir A, **Goff L**, El-Rifai W. Aurora kinase A in gastrointestinal cancers: time to target. *Molecular Cancer*, 14: 106, 2015. PMCID: PMC4436812.
15. Pauff JM, **Goff LW**. Current progress in immunotherapy for the treatment of biliary cancers. *Journal of Gastrointestinal Cancer*, 47(4):351-357, December 2016.
16. Mouli SK, **Goff LW**. Local arterial therapies in the management of unresectable hepatocellular carcinoma. *Current Treatment Options in Oncology*, 18(11):67, 2017.
17. Grieb BC, **Goff LW**, Goyal L, Denlinger CS. Evolving landscape of systemic therapy for hepatocellular carcinoma: breakthroughs, toxicities and future frontiers. *ASCO Educational Book*, 39: 248-260; 2019 .
18. Roth MT, **Goff LW**. Gemcitabine, cisplatin, and nab-paclitaxel for patients with advanced biliary tract cancer: closing the GAP. *JAMA Oncology*, 5(6): 831-832, 2019.
19. Gordan JD, Kennedy EB, Abou-Alfa GK, Brower ST, Gade TP, **Goff L**, Gupta S, Guy J, Harris WP, Iyer R, Jaiyesimi I, Jhaver M, Karipott A, Kaseb AO, Kelley RK, Knox JJ, Kortmansky J, Leaf A, Remak WM, Shroff RT, Shal DPS, Taddei TH, Venepalli NK, Wilson A, Zhu AX, Rose MG. Systemic therapy for advanced hepatocellular carcinoma: ASCO Guideline. *Journal of Clinical Oncology*, 38(36): 4317-4345, 2020.

Letters to editor, book reviews, editorials, etc.:

1. Pohlmann PR, Mernaugh RL, **Goff LW**. Chemotherapy and immunotherapy in metastatic colorectal cancer. *New England Journal of Medicine*, 360(20): 2135-6, 2009.
2. **Goff LW**. Brivanib fails to live up to the promise of early studies. *The ASCO Post*, 4(18): 44, 2013.
3. Shaikh F, **Goff L**. Decoding hepatocellular carcinoma: the promise of microRNAs. *Hepatobiliary Surgery and Nutrition*, 3(2): 93-4, 2014.
4. Roth M, **Goff LW**. Adjuvant therapy for biliary tract cancers advances. *Oncology Live*, 2017.

Abstracts:

1. Bekaii-Saab T, Phelps M, Li X, Motoyasu S, Kosuri K, **Goff L**, Kauh J, O'Neil B, South C, Thomas J, Balsom S, Chattah N, Balint C, Liersemann R, Vasko V, Marsh W, Doyle LA, Ellison G, Ringel M, Villalona Calero M. A multi-institutional study of AZD6244 (ARRY-142886) in patients with advanced biliary cancers. In: Proceedings of the 100th Annual Meeting of the American Association for Cancer Research; 2009 Apr 18-22; Denver, Colorado. Philadelphia (PA): AACR; 2009. Abstract LB-129.
2. O'Neil BH, **Goff LW**, Kauh J, Bekaii-Saab T, Strosberg JR, Lee R, Deal AM, Sullivan D, Sebt SM. A phase II study of AZD6244 in advanced or metastatic hepatocellular carcinoma. *Journal of Clinical Oncology* 27, 2009 (suppl; abstract e15574).
3. Infante JR, Berlin J, Bendell JC, **Goff LW**, Jones SF, Chan E, Rothenberg ML, Burris HA. Use of KRN330, a fully human antibody directed against A33, in the treatment of advanced colorectal cancer: results of the first phase I clinical trial. Presented at the 2010 Gastrointestinal Cancers Symposium, Orlando, FL.
4. Backlund DC, **Goff LW**, Chan E, Shyr Y, Conkright WA, Cornelius LA, Pakron SC, Holloway M, McClanahan P, Berlin J. A phase II trial of sorafenib and erlotinib in unresectable pancreas cancer: preliminary results. Presented at the 2010 Gastrointestinal Cancers Symposium, Orlando, FL.
5. O'Neil BH, Karapetis CS, **Goff LW**, Gupta N, Pradhan R, Qin Q, Ricker JL, McKee MD, Carlson DM, Goldberg RM, Berlin JD. Combination therapy with linifanib (ABT-869) and mFOLFOX6 for patients with metastatic colorectal cancer. Presented at the 2010 European Society for Medical Oncology World Congress on Gastrointestinal Cancer, Barcelona, Spain.
6. Adjei AA, Sosman JA, Martell RE, Dy GK, **Goff LW**, Ma WW, Horn L, Fetterly GJ, Michael SA, Means JA, Chai F, Lamar M, Strauss GM, Chiang W, Jarboe J, Schwartz BE, Puzanov I. Efficacy in selected tumor types in a phase I study of the c-MET inhibitor ARQ 197 in combination with sorafenib. Presented at the 2011 American Society of Clinical Oncology Annual Meeting, Chicago, IL.
7. Martell RM, Puzanov I, Ma W, Santoro A, Dy GK, **Goff LW**, Fetterly GJ, Michael SA, Means-Powell JA, Chai F, Lamar M, Simonelli M, Chiang WM, Jarboe J, Schwartz BE, Adjei AA. Safety and efficacy of MET inhibitor tivantinib (ARQ 197) combined with sorafenib in patients with hepatocellular carcinoma from a phase I study. Presented at the 2012 American Society of Clinical Oncology Annual Meeting, Chicago, IL.
8. Puzanov I, Sosman JA, Santoro A, Martell RE, Dy GK, **Goff LW**, Ma W, Fetterly GJ, Michael SA, Means-Powell JA, Chai F, Lamar M, Strauss GM, Zucali PM, Chiang WM, Jarboe J, Schwartz BE, Adjei AA. Safety and efficacy of MET inhibitor tivantinib (ARQ 197) combined with sorafenib in patients with renal cell carcinoma from a phase I study. Presented at the 2012 American Society of Clinical Oncology Annual Meeting, Chicago, IL.
9. Means-Powell JA, Adjei AA, Puzanov I, , Dy GK, **Goff LW**, Ma W, Fetterly GJ, Michael SA, Chai F, Lamar M, Schwartz BE, Sosman JA, . Safety and efficacy of MET inhibitor tivantinib (ARQ 197) combined with sorafenib in patients with *NRAS* wild-type or mutant melanoma from a phase I study. Presented at the 2012 American Society of Clinical Oncology Annual Meeting, Chicago, IL.
10. **Goff LW**, Borghaei H, Cohen RB, Berlin J, Noberasco C, Gallo Stampino C, Wang E, Williams JA, English PA, DeBraud F. Pharmacokinetic and pharmacodynamics analysis from a phase I study of PF-03446962, a fully human mab against ALK1, a TGF-beta receptor involved in tumor angiogenesis. Published at the 2012 American Society of Clinical Oncology Annual Meeting, Chicago, IL.
11. Wang E, Borghaei H, **Goff LW**, Noberasco C, Cohen RB, Gallo Stampino C, Williams JA, DeBraud F, Berlin J. Pharmacokinetic modeling and simulation supported dose escalation of PF-03446962, a monoclonal antibody against activin receptor like kinase 1, in patients with solid tumors. Presented at the 2012 American Society of Clinical Oncology Annual Meeting, Chicago, IL.
12. Ciombor KK, Cardin DB, Chan E, McClanahan P, Fan K, Flynn J, Young RT, DeMers A, Smith SJ, Berlin J, **Goff, LW**. Phase Ib study of gemcitabine and oxaliplatin with erlotinib in patients with advanced biliary tract cancer. Published at the 2012 American Society of Clinical Oncology Annual Meeting, Chicago, IL.
13. Chan E, Arlinghaus LR, Cardin DB, **Goff LW**, Yankeelov TE, Berlin J, McClanahan P, Holloway M, Parikh AA, Abramson RG, Merchant NB, Hiebert S, Chakravarthy AB. Phase I trial of chemoradiation with capecitabine and vorinostat in pancreatic cancer. Presented at the 2013 American Society of Clinical Oncology Gastrointestinal Cancers Symposium, San Francisco, CA.

14. Cardin DB, **Goff LW**, Chan E, Holloway M, McClanahan P, Shyr Y, Li C, Meyer K, Grigorieva J, Berlin J. Phase II trial of sorafenib and erlotinib in unresectable pancreas cancer: final results and correlative findings. Presented at the 2013 American Society of Clinical Oncology Gastrointestinal Cancers Symposium, San Francisco, CA.
15. Thota R, **Goff L**, Chan E, Berlin J, Jones C, McClanahan P, Ayers G, Cardin D. A phase II study of ganetespib as second- or third-line therapy for metastatic pancreatic cancer. Presented at the 2014 American Society of Clinical Oncology Gastrointestinal Cancers Symposium, San Francisco, CA.
16. Simonelli M, Denlinger CS, **Goff LW**, Noberasco C, Kim TY, Thomas MB, DeBraud FG, Zucali PA, Santoro A, English PA, Gallo Stampino C, Wang E, Carpentieri M, Williams JA. Phase 1 study of PF-03446962 (anti-ALK-1 mAb) in hepatocellular carcinoma: correlation of tumor and serum biomarker data with disease control. Presented at the 2014 American Society of Clinical Oncology Annual Meeting, Chicago, IL.
17. Chan E, **Goff LW**, Cardin DB, Berlin J, Levy MA, Vnencak-Jones CL, Pao W. Routine multiplexed mutational analysis of colorectal cancers: a single-institution experience. Presented at the 2015 American Society of Clinical Oncology Gastrointestinal Cancers Symposium, San Francisco, CA.
18. Cardin DB, **Goff LW**, Chan E, Whisenant J, Arlinghaus LR, Yankeelov T, Koyama T, Berlin J, Merchant NB. Phase I study of gemcitabine, dasatinib, and erlotinib in advanced pancreatic carcinoma. Presented at the 2017 American Society of Clinical Oncology Gastrointestinal Cancers Symposium, San Francisco, CA.
19. Bang YJ, Golan T, Lin C, Kang Y, Wainberg ZA, Wasserstrom HA, Jin J, Mi G, McNeely S, Liang N, **Goff LW**, Fu S. Interim safety and clinical activity in patients with locally advanced and unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma from a multicohort phase I study of ramucirumab plus durvalumab. Presented at the 2018 American Society of Clinical Oncology Gastrointestinal Cancers Symposium, San Francisco, CA.
20. Das S, Cardin DB, **Goff LW**, Berlin J, Schulte M, Manning HC, Coffey RJ, Whisenant J, Krumsick R, Ciombor KK. Novel PET/CT imaging biomarkers of CB-839 in combination with panitumumab and irinotecan in patients with metastatic and refractory RAS wildtype colorectal cancer: a phase I/II study. Presented at the 2018 American Society of Clinical Oncology Annual Meeting, Chicago, IL.
21. Wei AC, Ou F, Shi Q, Carrero X, O'Reilly EM, Meyerhardt J, Wolff RA, Kindler HL, Evans DB, Deshpande V, Misdraji J, Tamm E, Sahani D, Moore M, Newman E, Merchant N, Berlin J, **Goff LW**, Pisters P, Posner MP. A phase II study of pre- and post-operative gemcitabine and erlotinib plus pancreaticoduodenectomy for patients with resectable pancreatic ductal adenocarcinoma: ACOSOG Z5041 trial. Presented at the 2018 American Society of Clinical Oncology Annual Meeting, Chicago, IL.
22. Ciombor KK, Whisenant JG, Cardin DB, **Goff LW**, Das S, Schulte ML, Cohen A, Coffey RJ, Ayers GD, Krumsick R, Demo S, Whiting S, Manning HC, Berlin JD. CB-839, panitumumab, and irinotecan in RAS wildtype metastatic colorectal cancer: phase I results. Presented at the 2019 American Society of Clinical Oncology Gastrointestinal Cancers Symposium, San Francisco, CA.
23. Das S, Ciombor KK, Haraldsdottir S, Pumpalova YS, Sahin IH, Shyr Y, Chu S, Lin EP, Hsu C, **Goff LW**, Cardin DC, Bilen MA, Berlin J, Wu C. Immune checkpoint inhibitors in gastrointestinal cancer: immune related adverse events and efficacy. Presented at the 2019 American Society of Clinical Oncology Annual Meeting, Chicago, IL.
24. Bang YJ, Golan T, Lin C, Daha L, Fu S, Moreno V, Geva R, Reck M, Wasserstrom HA, Mi G, Laing N, **Goff LW**. Ramucirumab and durvalumab treatment of metastatic non-small cell lung cancer, gastric/gastroesophageal junction adenocarcinoma, and hepatocellular carcinoma following progression on systemic treatments. Presented at the 2019 American Society of Clinical Oncology Annual Meeting, Chicago, IL.
25. Pappas L, Reyes S, Lanka A, Shroff RT, Le TM, Rahma OE, Bocobo AG, Borad MJ, DeLeon T, Mody K, Roth MT, Peters MLB, **Goff LW**, Boyhen K, Van Cott C, Horick N, Zhu AX, Javle MM, Kelley RK, Goyal L. Presented at the 2020 American Society of Clinical Oncology Gastrointestinal Cancers Symposium, San Francisco, CA.
26. Yarchoan M, Cope L, Anders RA, Noonan A, **Goff LW**, Goyal L, Lacy J, Li D, Patel A, He AR, Abou-Alfa G, Spencer K, Kim E, Xavier S, Ruggieri A, Davis SL, McRee A, Kunk P, Zhu Q, Wang-Gillam A, Poklepovic A, Chen H, Sharon E, Lesinski GB, Azad N. A multicenter randomized phase 2 trial of atezolizumab as monotherapy or in combination with cobimetinib in biliary tract cancers; an NCI Experimental Therapeutics Clinical Trials Network (ETCTN) study. Presented at the 2020 American Association of Cancer Research Annual Meeting, held virtually.
27. Das, S, Du L, Thomas K, Schad A, Jain S, Jessop A, Shah C, Eisner D, Cardin DB, Ciombor KK, **Goff LW**, Bradshaw M, Delbeke D, Sandler MP, Berlin J. Validation of a clinical score for patients with well-differentiated neuroendocrine tumors under consideration for peptide receptor radionuclide therapy with Lu 177 dotatate. Presented at the 2021 American Society of Clinical Oncology Gastrointestinal Cancers Symposium, held virtually.
28. He AR, Kim AY, Toskich BM, Mody K, Kim K, Stein S, Goyal L, Abrams TA, Brown D, **Goff LW**, Kim RD, Parikh N, Sandow T, Johnson D, Iyer RV, Petroziello M, Krishnamurthi SS, Martin C, Jiang Y, Akhter N. A phase II study of atezolizumab and bevacizumab in combination with Y90 TARE in patients with

hepatocellular carcinoma. Presented at the 2021 American Society of Clinical Oncology Gastrointestinal Cancers Symposium, held virtually.

29. Das, S, Chauhan A, Du L, Thomas K, Jacob A, Schad A, Jain S, Jessop A, Shah C, Eisner D, Cardin DB, Ciombor KK, **Goff LW**, Bradshaw M, Delbeke D, Sandler MP, Berlin J, Ramirez RA. Validation of a clinical score for patients with well-differentiated neuroendocrine tumors under consideration for peptide receptor radionuclide therapy with Lu 177 dotatate. Presented at the 2021 American Society of Clinical Oncology Annual Meeting, held virtually.
30. Droz dit Busset M, Shaib WL, Mody K, Personeni N, Damjanov N, Harris WP, Bergamo F, Brandi G, Masi G, Halfdanarson T, Tam V, **Goff LW**, Knox J, Hollebecque A, Macarulla T, Cantero F, Saulay M, Braun S, Javle MM, Borad MJ. Derazantinib for patients with intrahepatic cholangiocarcinoma harboring *FGFR2* fusions/rearrangements: primary results from the Phase 2 study FIDES-01. Presented at the European Society of Medical Oncology Congress, held virtually September 2021

Presentations at Scientific Meetings:

1. "The EGFR axis in the early rash of patients treated with EGFR inhibitors." **Williams LA**, Washington MK, Berlin JD, Lockhart A, Johnson DH, Chan E, Trivedi B, Backlund D, LaFleur B, Rothenberg ML, Coffey RJ. In: Proceedings of the 99th Annual Meeting of the American Association for Cancer Research; 2008 Apr 12-16; San Diego, CA. Philadelphia (PA): AACR; 2008. Abstract 2167. Poster, peer-reviewed.
2. "Colorectal Cancer: Reviewing Standards of Care to Reach a Cure." **Laura Goff** and Paul Wise. Annual Scientific Assembly of the Southern Medical Association. August 8, 2008, Nashville, TN. Invited oral presentation.
3. "A phase II study of IMGN242 (huC242-DM4) in patients with CanAg-positive gastric or gastroesophageal junction cancer." **Goff LW**, Papadopoulos K, Posey JA, Phan AT, Patnaik A, Miller JG, Zildjian S, O'Leary JJ, Qin A, Tolcher A. *Journal of Clinical Oncology* 27, 2009 (suppl; abstract e15625). Poster, peer-reviewed.
4. "A phase I clinical and biological evaluation of combined epidermal growth factor receptor blockade with erlotinib and cetuximab in patients with advanced cancer." **Goff LW**, Chan E, Backlund DC, LaFleur B, Merchant NB, Washington MK, Manning HC, Rothenberg ML, Coffey RJ, Berlin JD. Presented at the 2010 Gastrointestinal Cancers Symposium, Orlando, FL. Poster, peer-reviewed.
5. "Phase 1 study of PF-03446962, a fully human monoclonal antibody against activin receptor-like kinase 1, a transforming growth factor-beta receptor involved in tumor angiogenesis." **Goff LW**, DeBraud F, Borghaei H, Berlin J, Noberasco C, Cohen RB, Lyshchik A, Wang E, Hu-Lowe D, Levin W, Tuthill T, Shalinsky D, Abbattista A, Lappin P, Gallo Stampino C. Presented at the 2010 American Society of Clinical Oncology Annual Meeting, Chicago, IL. Poster, peer-reviewed.
6. "Advances in the Systemic Treatment of Biliary Cancers." **Laura Goff**. Chemotherapy Foundation Symposium, November 10, 2010, New York, NY. Invited oral presentation.
7. "Phase 1 study of PF-03446962, a fully human monoclonal antibody against activin receptor-like kinase 1, a transforming growth factor-beta receptor involved in tumor angiogenesis." **Goff LW**, Cohen RB, Berlin J, Noberasco C, Borghaei H, Gallo-Stampino C, Wang E, Hu Lowe D, Levin WJ, De Braud FG. Oral presentation at the 2011 American Society of Clinical Oncology Annual Meeting, Chicago, IL, peer-reviewed.
8. "A phase I study of PF-03446962, an ALK-1 (activin-receptor-like kinase-1) inhibitor, in patients with advanced or metastatic solid tumors." **Laura Goff**. The 14th International Symposium on Anti-Angiogenic Therapy, February 3, 2012, San Diego, CA. Invited oral presentation.
9. "The association of HGF/Cmet overexpression with clinicopathologic factors in hepatocellular carcinoma." **Goff LW**, Shaikh FY, Du L, Washington MK, Salaria SN. Presented at the 2015 Gastrointestinal Cancers Symposium, San Francisco, CA. Poster, peer-reviewed.
10. "Discussion." **Laura Goff**. Oral Abstract Session: Cancers of the Pancreas, Small Bowel and Hepatobiliary Tract, 2015 Gastrointestinal Cancers Symposium, San Francisco, CA. Invited Discussant.
11. "Phase I study combining the aurora kinase A (AURKA) inhibitor alisertib with mFOLFOX in gastrointestinal cancer." **Goff LW**, Azad N, Stein S, Whisenant JG, Koyama T, Vaishampayan U, Hochster H, Connolly R, Weise A, LoRusso P, El-Rifai W, Berlin JD. Presented at the 2017 American Society of Clinical Oncology Annual Meeting, Chicago, IL. Poster, peer-reviewed.
12. "North American Collaborations in Biliary Cancers." **Laura Goff**. Cholangiocarcinoma Foundation Annual Conference 2019, Salt Lake City, UT. Invited speaker.
13. "Sequencing Systemic Therapy in Hepatocellular Carcinoma—Immune Checkpoint Inhibitor or TKI First?" **Laura Goff** Education Session, 2019 American Society of Clinical Oncology Annual Meeting, Chicago, IL. Invited speaker.
14. "Managing adverse events associated with targeted therapies." Crystal Denlinger and **Laura Goff**. Cholangiocarcinoma Summit, 2019, Phoenix, AZ. Invited speaker.
15. "What's on the horizon for all-comer studies?" **Laura Goff**. Cholangiocarcinoma Foundation Annual Conference 2020, held virtually. Invited speaker.

16. "Optimizing treatment in advanced hepatocellular carcinoma: more questions than answers." **Laura Goff**. International Society of Gastrointestinal Oncology Annual Meeting 2020, held virtually. Invited speaker.
17. "How to target rare alterations in cholangiocarcinoma." **Laura Goff**. Cholangiocarcinoma Summit, 2020, held virtually. Invited speaker.